checkAd
    Startseite > Aktien > Dyne Therapeutics > Nachrichten
    Dyne Therapeutics Aktie
    29,38
     
    USD
    +4,33 %
    +1,22 USD
    Letzter Kurs 02:00:00 Nasdaq
    29,38
     
    USD
    1.000 STK
    Geldkurs 15.05.24
    29,43
     
    USD
    100 STK
    Briefkurs 15.05.24
    ISIN: US26818M1080 · WKN: A2QB6B · SYM: DYN · USA

    Neueste Nachrichten

    Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
    02.05.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
    27.03.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
    27.03.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics Announces CEO Transition
    25.03.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
    13.03.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    05.03.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
    14.02.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics to Present at February Investor Conferences
    01.02.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    11.01.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
    05.01.24 · globenewswire · Dyne Therapeutics
    Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
    05.01.24 · globenewswire · Dyne Therapeutics
    ROUNDUP/Aktien New York Schluss: Fed-Protokoll ändert nichts am mauen Start 2024
    03.01.24 · dpa-AFX · Amgen